Literature DB >> 9366392

Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation.

E W Hewitt1, A Treumann, N Morrice, P J Tatnell, J Kay, C Watts.   

Abstract

Cathepsin E is an aspartic proteinase that has been implicated frequently in Ag processing for presentation on class II MHC molecules, but no information exists on its cleavage specificity within Ags in relation to known T cell epitopes. We have analyzed the processing by cathepsin E of a large C-terminal domain of tetanus toxin (residues 872-1315), and we have compared the processing products with those liberated by cathepsin D, a related aspartic proteinase also thought to be involved in class II MHC-restricted Ag processing. Processing products were analyzed by N-terminal Edman degradation and mass spectrometry following reverse-phase HPLC separation of peptides. A total of 28 cleavage sites was identified, 11 of which were recognized by both cathepsins E and D. Most, although not all, sites were between pairs of hydrophobic residues and were located within the 200-amino-acid C terminal region known to contain several human T cell epitopes. Previously described T cell epitopes, for example, between residues 1273 and 1284, were flanked by cathepsin E and D cleavage sites. These data are consistent with an important role for cathepsins E and/or D in Ag processing in the human immune system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366392

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain inovalbumin-immunized mice.

Authors:  T Zhang; Y Maekawa; J Hanba; T Dainichi; B F Nashed; H Hisaeda; T Sakai; T Asao; K Himeno; R A Good; N Katunuma
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  Differing processing requirements of four recombinant antigens containing a single defined T-cell epitope for presentation by major histocompatibility complex class II.

Authors:  L Colledge; M Y Sun ; W Lin; C C Blackburn; P A Reay
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

3.  The preparation of neoglycoconjugates containing inter-saccharide phosphodiester linkages as potential anti-Leishmania vaccines.

Authors:  F H Routier; A V Nikolaev; M A Ferguson
Journal:  Glycoconj J       Date:  1999-12       Impact factor: 2.916

4.  Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D.

Authors:  D C Pimenta; V C Chen; J Chao; M A Juliano; L Juliano
Journal:  J Protein Chem       Date:  2000-07

Review 5.  Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines.

Authors:  A V Nikolaev; O V Sizova
Journal:  Biochemistry (Mosc)       Date:  2011-07       Impact factor: 2.487

6.  CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting.

Authors:  F Rodriguez; S Harkins; J M Redwine; J M de Pereda; J L Whitton
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Reconstruction of a pathway of antigen processing and class II MHC peptide capture.

Authors:  Catherine X Moss; Timothy I Tree; Colin Watts
Journal:  EMBO J       Date:  2007-03-29       Impact factor: 11.598

8.  The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.

Authors:  Jerome Kerzerho; Aurélie Schneider; Emmanuel Favry; Florence Anne Castelli; Bernard Maillère
Journal:  J Biol Chem       Date:  2013-04-03       Impact factor: 5.157

Review 9.  Cathepsin G: roles in antigen presentation and beyond.

Authors:  Timo Burster; Henriette Macmillan; Tieying Hou; Bernhard O Boehm; Elizabeth D Mellins
Journal:  Mol Immunol       Date:  2009-11-11       Impact factor: 4.407

10.  Cathepsin D is up-regulated in inflammatory bowel disease macrophages.

Authors:  M Hausmann; F Obermeier; K Schreiter; T Spottl; W Falk; J Schölmerich; H Herfarth; P Saftig; G Rogler
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.